The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.
Description: The primary endpoint is to determine the overall response rate (ORR=CR+PR) as documented by RECIST v1.1 criteria within each cohort.Measure: Overall response rate Time: 1 year
There are 3 SNPs
V600E, V600K, V600D). --- V600E --- --- V600K --- --- V600D ---
V600E, V600K, V600D). --- V600E ---
V600E, V600K, V600D). --- V600E --- --- V600K ---